Endocrine Month in Review: May 2022

1. Tirzepatide (Mounjaro) Wins FDA Approval for Type 2 Diabetes

• Announced on May 13, the US FDA approved tirzepatide (Mounjaro) as an adjunct to diet and exercise for improving blood sugar in adults with type 2 diabetes.
• A first-in-class dual GLP-1/GIP agonist, approval was based on data from the SURPASS program and is expected to be available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses.
  

2. Diabetes Dialogue: Tirzepatide in Action & AACE 2022 Recap

• Recorded less than a week after approval, the latest episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives broke down what the tirzepatide approval means for clinicians and patients.
• Later in the episode, hosts take a deep dive into their takeaways from the American Association of Clinical Endocrinology (AACE) 2022 annual meeting and discuss how a recent acquisition by a major company might impact care in the future.
  

3. iLet Bionic Pancreas Shows Promise in Pivotal Trial

• Data from the Insulin-Only Bionic Pancreas Pivotal Trial was presented at the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD).
• Results of the study suggest use of the iLet Bionic Pancreas, produced by Beta Bionics Inc., was associated with significant reductions in HbA1c and improved time in range compared with standard care in patients with type 1 diabetes.
  

4. Thyroid Dysfunction Could Increase Risk of Parkinson Disease

• A systematic review and meta-analysis presented at AACE 2022 examined the risk of Parkinson disease among patients with hypothyroidism and hyperthyroidism.
• Results of the study indicated patients with thyroid dysfunction were at increased risk of Parkinson disease, with increases in likelihood of 56% and 57% for hypothyroidism and hyperthyroidism, respectively.
  

5. Diabetes Dialogue: ATTD 2022 Recap

• Our first episode in May, this episode of Diabetes Dialogue was dedicated to discussions surrounding ATTD 2022.
• Highlights of the episode include reactions to the SURMOUNT-1 topline results and a deep dive into our hosts’ favorite sessions from the conference, including the latest updates in the world of diabetes smartphone apps, smart insulin pens, and CGM systems.
  

6. Metformin, Lifestyle Interventions Can Prevent T2D, But Do Little for CVD Risk in Prediabetes

• The latest update from the Diabetes Prevention Program Outcomes Study (DPPOS) suggests neither metformin nor lifestyle interventions were associated with a reduction in risk of major adverse cardiovascular events.
• In adjusted analyses with a time-weighted mean follow-up of 21 years, no reduction in risk was observed for MACE based on use of metformin (HR, 1.03 [95% CI, 0.78-1.37]; P=.81) or lifestyle interventions (HR, 1.14 [95% CI, 0.87-1.50]; P=.34).